RDGL News - Candlesense

Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA

Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission.

Could this event trigger any covenant breaches or affect debt covenants in Vivos Inc.'s financing agreements? What is the market's perception of management's ability to navigate regulatory hurdles moving forward? How might this news influence analyst ratings and target price revisions for RDGL?

Clinical trials

10 days ago